Harleysville, PA, United States of America

Theresa M Williams

This inventor holds 61 USPTO granted patents and 13 published patent applications and 13 EPO patents, primarily in Cancer Treatment Compounds (CPC class C07D). Top assignees: Merck + Co., Inc., Shy Therapeutics LLC, Merck Sharp + Dohme Corp.. Active years: 1991-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Theresa M Williams. Retrieved from https://idiyas.com/inventor/theresa-m-williams

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 61 (Patent Applications = 13)

% Patents Active = 93.4

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 3.8

ph-index = 18

Forward Citations = 1,118(Granted Patents)

Forward Citations (Not Self Cited) = 1,067(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Lansdale, PA (US) (1991)
Harleysville, NJ (US) (2007 - 2009)
Harleysville, PA (US) (1992 - 2023)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

4. 1 out of 834,570

Other

patents

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

Cancer Treatment

Ras Superfamily

Inflammatory Diseases

CGRP Receptor Antagonists

Prenyl-Protein Transferase

Farnesyl-Protein Transferase

Spirolactam Compounds

Heterocyclic Benzodiazepine

Imidazole Compounds

Biaryl Compounds

Anilide Compounds

Spirohydantoin Compounds

61 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653810 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2026-06-16),

2. 12459951 - Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2025-11-04),

3. 12391705 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2025-08-19),

4. 12168668 - Compounds for the treatment of cancer and inflammatory disease (2024-12-17),

5. 11560390 - Compounds for the treatment of cancer and inflammatory disease (2023-01-24),

6. 11541041 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease (2023-01-03),

7. 11213515 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2022-01-04),

8. 11026930 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-06-08),

9. 11000515 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-05-11),

10. 10940139 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-03-09),

11. 10933054 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-03-02),

12. 10870657 - Compounds for the treatment of cancer and inflammatory disease (2020-12-22),

13. 10588894 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2020-03-17),

14. 10221191 - Compounds for the treatment of cancer and inflammatory disease (2019-03-05),

15. 8039460 - CGRP receptor antagonists (2011-10-18),

Title: Innovations in Cancer Treatment by Theresa M. Williams

Introduction

Theresa M. Williams, based in Harleysville, PA, is a prolific inventor with an impressive portfolio of 58 patents. Her contributions primarily focus on compounds targeted for the treatment of cancer and inflammatory diseases. With a strong background in pharmaceutical research, Williams has made significant strides in developing new therapies that have the potential to enhance treatment outcomes for patients battling these serious health conditions.

Latest Patents

Among her latest inventions, Williams has developed innovative compounds aimed at inhibiting the phosphorylation of MAPK. These compounds are pivotal in compositions and methods designed for treating cancer and inflammatory diseases. Her work in this area reflects a deep understanding of the molecular mechanisms involved in disease progression and offers promising avenues for new therapeutic strategies.

Career Highlights

Throughout her career, Williams has held key roles in renowned companies such as Merck & Company, Inc. and Shy Therapeutics LLC. Her experience in these organizations has not only contributed to her extensive patent portfolio but has also enabled her to collaborate with other leading scientists and researchers in the field of oncology and pharmacology.

Collaborations

Williams has collaborated with notable colleagues, including Christopher J. Dinsmore and Christopher S. Burgey. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and the development of groundbreaking therapies that address pressing medical needs.

Conclusion

Theresa M. Williams continues to be a key figure in the realm of cancer research and treatment. With her extensive patent record and experience in leading pharmaceutical companies, she exemplifies the spirit of innovation that is crucial in the relentless pursuit of effective medical solutions. Her ongoing research holds great promise for the future of cancer and inflammatory disease treatments, embodying the transformative power of science in healthcare.

Profile summary based on public USPTO records.